Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura
NCT02614846Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Aug 2015
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of hetrombopag in immune thrombocytopenia (ITP), sponsored by Hengrui. Primary endpoint: Number of subjects with adverse events. Status: unknown.
02
Drugs
hetrombopag
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT02614846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02614846.